Medgenics Finds Success In Biopump Tissue Technology

Medgenics has announced that one of the patients treated with the EPODURE tissue Biopumps continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. The patient was treated with EPODURE almost 11 months ago. He was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of three tiny EPODURE tissue Biopumps in the phase I/II anemia trial in Israel.

The company claims that the patient has gone a full year without his last EPO injection, while his hemoglobin level has been continuously maintained within the target range of 10-12 g/dl for this period. The company plans to present the study at the upcoming American Society of Nephrology in October.

Anatole Besarab, a member of Scientific Advisory Board at Medgenic, said: “With a patient now nearing 12 months without EPO injections and others for more than 6 months, it is becoming clearer that the EPODURE Biopump is able to produce sufficient erythropoietin to effectively elevate and then sustain hemoglobin levels in patients with sufficient administered dose. I am not aware of any other technology that can achieve such prolonged and sustained therapy from a single treatment. Additional studies are needed in a broader range of patients, and we look forward to them to further confirm these very positive results.”

In addition, Medgenics is in discussions with major pharmaceutical companies and with institutional investment funds, to co-develop Biopump producing Factor VIII protein for the treatment of hemophilia.

Andrew Pearlman, CEO of Medgenics, said: Company continues its focused efforts to raise several million US $ in the coming months to enable it to continue and expand the clinical trial and our other operations and to realize the potential of the great opportunities it now has.